Barata, PC;
De Liano, AG;
Mendiratta, P;
Crolley, V;
Szabados, B;
Morrison, L;
Wood, L;
... Rini, BI; + view all
(2018)
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.
British Journal of Cancer
, 119
(2)
pp. 160-163.
10.1038/s41416-018-0104-z.
Preview |
Text
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.pdf - Published Version Download (315kB) | Preview |
Abstract
Background: The outcome of patients who progress on front-line immune-based combination regimens (IC) including immune checkpoint inhibitors (CPI) and receive subsequent systemic therapy is unknown. / Methods: Retrospective analysis of consecutive patients with clear-cell mRCC who progressed on one of seven clinical trials investigating an IC and received ≥1 line of subsequent VEGFR TKI therapy. / Results: Thirty-three patients [median age 57 (37–77), 85% male, 73% ECOG 0] were included. For evaluable patients (N = 28), the best response to first subsequent therapy was 29% partial response, 54% stable disease, and 18% progressive disease. The median PFS (mPFS) for first subsequent therapy was 6.4 months (95% CI, 4.4–8.4); no difference in mPFS by prior type of IC (VEGFR TKI-CPI vs. CPI-CPI) was noted (p = 0.310). Significant AEs were observed in 30% of patients, more frequently transaminitis (9%). / Conclusions: VEGFR TKIs have clinical activity in mRCC refractory to IC therapy, possibly impacted by the mechanism of prior combination therapy.
| Type: | Article |
|---|---|
| Title: | The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41416-018-0104-z |
| Publisher version: | https://doi.org/10.1038/s41416-018-0104-z |
| Language: | English |
| Additional information: | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| Keywords: | Cancer, Renal cancer |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10110708 |
Archive Staff Only
 |
View Item |
